Cost-effectiveness and drug wastage of bevacizumab biosimilar with or without chemotherapy for platinum-resistant recurrent ovarian cancer
CONCLUSIONS: Bevacizumab biosimilars in mg/kg dosage form with chemotherapy are still not cost-effective in Taiwan, but using weight-based dosing will reduce drug waste and save treatment costs.PMID:38372034 | DOI:10.1080/14737167.2024.2319605
Source: Expert Review of Pharmacoeconomics and Outcomes Research - Category: Health Management Authors: Shih Ping Lai Shyh-Yau Wang Agnes Lf Chan John Hang Leung Hei-Tung Yip Source Type: research
More News: Avastin | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Health Management | Ovarian Cancer | Ovaries | Taiwan Health